Related Experiment Videos
Public health and hepatitis C
D M Patrick1, J A Buxton, M Bigham
1Communicable Disease Epidemiology Services, UBC Centre for Disease Control, Vancouver. david.patrick@bccdc.hnet.bc.ca
Summary
Hepatitis C (HCV) surveillance and prevention in Canada are primarily impacted by injection drug use (IDU), with current harm reduction strategies proving ineffective. New public health policies and improved preventive strategies are urgently needed to control the epidemic.
Area of Science:
- Public Health
- Epidemiology
- Infectious Disease Control
Background:
- Hepatitis C is a reportable disease across Canada, with an overall prevalence under 1%.
- Injection drug use (IDU) is the primary driver of Hepatitis C Virus (HCV) infections in Canada, accounting for up to 90% of cases.
- New HCV infections are largely defined by IDU, with incidence rates exceeding 25% among new injectors.
Purpose of the Study:
- To review key public health aspects of Hepatitis C (HCV) surveillance.
- To examine the transmission dynamics of HCV, particularly concerning injection drug use.
- To evaluate primary prevention strategies for HCV in the Canadian context.
Main Methods:
- Review of public health data and literature on HCV surveillance.
- Analysis of epidemiological trends related to HCV transmission.
- Assessment of current and proposed prevention and harm reduction strategies for HCV.
Main Results:
- HCV epidemiology in Canada is predominantly characterized by IDU.
- Existing harm reduction strategies targeting IDU have been underdeployed and ineffective in epidemic control.
- An effective HCV vaccine is not yet available; some offer Hepatitis A and B vaccines to infected individuals.
Conclusions:
- Current HCV control efforts in Canada are insufficient, largely due to the ineffectiveness of harm reduction strategies for IDU.
- Novel public health policies, including potential drug regulation, are under consideration.
- Urgent development and rigorous evaluation of improved HCV preventive strategies are critical.